Latest Breaking News On - Mizuho japan - Page 1 : vimarsana.com

CytoSorb® Registered and Commercially Available in Singapore CytoSorbents announces immediate commercial availability of CytoSorb in Singapore through distributor Humedical News provided by Share this article MONMOUTH JUNCTION, N.J., May 25, 2021 /PRNewswire/ CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in the intensive care unit (ICU) and cardiac surgery, announces that the Singapore Health Sciences Authority (HSA) has now approved registration of CytoSorb® for all equivalent European Union (E.U.) approved indications, including the reduction of cytokine storm, the reduction of bilirubin in liver disease, the reduction of myoglobin in trauma, and the removal of ticagrelor and rivaroxaban during urgent or emergent cardiothoracic surgery.

United statesStefan baudisEric kimAmy vogelGerwin gerkeUs department of healthHuman servicesMaterial commandNational institutes of healthUs airEuropean unionUs armyBlood instituteNational heartGlobal affairs at cytosorbentsCytosorbents corporation